CDCA3 also has been found to be a good biomarker candidate to predict the prognosis of renal cell carcinoma and kidney renal papillary cell carcinoma patients.[13,14] We have reported that knockdown of CDCA3 potentially suppressed PCa progression via the significant accumulation of p21 and via inhibiting the expression of cyclin D1 by regulating the NF-κB signaling pathway.[15] The study aims to determine whether CDCA3 is associated with prognosis and clinicopathological characteristics in PCa and identify possible downstream target genes co-expressed with CDCA3. The gene discussed is CCND1; the disease is posterior cortical atrophy.